Maternal–Fetal Pharmacokinetic Modeling Across Pregnancy

Abstract

Maternal–fetal pharmacokinetic (PK) modeling is an advanced computational approach designed to understand and predict drug disposition in pregnant women and their fetuses. Given the dynamic physiological changes during gestation, traditional pharmacokinetic paradigms often fail to capture the complexities inherent to maternal and fetal drug exposures. This review synthesizes current scientific evidence on maternal–fetal PK modeling, highlights mechanistic insights into drug transfer across the placenta, and discusses implications for clinical practice. We emphasize recent advances in physiologically based pharmacokinetic (PBPK) modeling, the impact of maternal disease states, and guideline recommendations for optimizing drug therapy in pregnancy.

Introduction

The pharmacokinetics of drugs in pregnant women significantly differ from those in the non-pregnant population due to profound physiological, biochemical, and anatomical changes. These modifications, which encompass alterations in plasma volume, renal filtration, hepatic metabolism, and placental function, can affect drug absorption, distribution, metabolism, and excretion (ADME). Maternal–fetal PK modeling leverages computational tools to simulate and predict drug disposition, aiming to improve therapeutic efficacy and minimize risks to both mother and fetus. Understanding these models is crucial for clinicians managing drug therapies in the obstetric population.

Epidemiology / Disease Burden

Medication use during pregnancy is widespread, with studies indicating that over 90% of pregnant women are prescribed or self-administer at least one medication. The prevalence of chronic diseases such as hypertension, diabetes, and epilepsy in pregnancy has risen, further increasing the need for rational pharmacotherapy. Inadequate dosing can result in therapeutic failure or fetal toxicity, underscoring the necessity for precise PK modeling to guide clinical decisions. Furthermore, congenital anomalies and adverse pregnancy outcomes have been linked to inappropriate drug exposure, highlighting the public health significance of optimizing pharmacotherapy through robust PK models.

Pathophysiology

Pregnancy induces a spectrum of physiological changes that alter drug kinetics. Key adaptations include increased plasma volume and cardiac output, reduced albumin concentration, elevated glomerular filtration rate, and modified hepatic enzyme activity. The placenta, functioning as both a barrier and a conduit, regulates drug transfer via passive diffusion, active transporters, and metabolic enzymes. These mechanisms collectively influence fetal drug exposure, necessitating mechanistic modeling to predict maternal–fetal drug concentrations accurately. Furthermore, specific disease states, such as preeclampsia or gestational diabetes, may further perturb these physiological processes, complicating PK predictions.

Risk Factors

Several risk factors impact maternal–fetal drug kinetics, including gestational age, maternal comorbidities, polypharmacy, genetic polymorphisms affecting drug metabolism, and variations in placental transporter expression. The timing of drug exposure is particularly critical, as teratogenic risk varies across trimesters. Additionally, fetal genetic variability in metabolic enzymes may influence drug response and toxicity, further complicating risk assessment.

Clinical Features

Clinically, altered drug kinetics during pregnancy may manifest as reduced efficacy or increased toxicity of medications. For example, increased clearance of antiepileptic drugs can result in breakthrough seizures, while reduced elimination of renally excreted drugs can enhance toxicity. Fetal drug exposure may present as growth restriction, congenital anomalies, or neonatal withdrawal syndromes, depending on the drug class and timing of exposure. Recognition of these features requires vigilance and tailored therapeutic strategies.

Diagnosis

Diagnosis of altered maternal–fetal drug kinetics is primarily based on clinical assessment, therapeutic drug monitoring, and, increasingly, model-informed precision dosing. Laboratory tests may evaluate drug concentrations in maternal blood, cord blood, or amniotic fluid. Advanced PK models, including PBPK, leverage patient-specific parameters such as organ size, blood flow, and enzyme activity to simulate drug disposition and guide dosing.

Treatment & Management

Optimal pharmacotherapy in pregnancy requires individualized dosing strategies informed by maternal–fetal PK models. These approaches incorporate patient-specific factors (weight, renal function, gestational age), drug properties (molecular weight, lipophilicity, protein binding), and placental transfer mechanisms. Therapeutic drug monitoring remains essential for drugs with narrow therapeutic indices. Collaborative care involving obstetricians, clinical pharmacologists, and pharmacists is recommended to ensure safe and effective therapy.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in maternal–fetal PK modeling, particularly with the application of PBPK and nonlinear mixed-effects models. These tools integrate in vitro data, in silico simulations, and clinical observations to improve predictions of drug behavior across pregnancy stages. Emerging research focuses on integrating genomics, placental transporter data, and real-world outcomes into PK models. Machine learning approaches are increasingly being explored to enhance model accuracy and facilitate rapid, individualized dosing recommendations. Efforts are also underway to validate these models with clinical trial data and to develop models for understudied populations, including women with multiple comorbidities.

Guideline Recommendations

Major regulatory bodies and professional societies now advocate for the use of model-informed dosing in the management of pregnant women requiring pharmacotherapy. Guidelines emphasize the need for preclinical PK studies in pregnancy, incorporation of PK modeling in clinical trial design, and routine use of therapeutic drug monitoring for high-risk drugs. The U.S. FDA and EMA have issued guidance documents outlining best practices for PK modeling and simulation in drug development for the pregnant population. These recommendations underscore the importance of multidisciplinary collaboration and ongoing research to refine PK models and improve clinical outcomes.

Conclusion

Maternal–fetal pharmacokinetic modeling represents a critical advancement in optimizing pharmacotherapy during pregnancy. By integrating physiological, biochemical, and clinical data, these models provide mechanistic insights into drug disposition and support evidence-based dosing decisions. Continued innovation in PK modeling, informed by real-world data and emerging technology, holds the promise of safer, more effective drug therapy for pregnant women and their fetuses. Ongoing education, research, and guideline development are essential to fully realize the benefits of model-informed precision dosing in this unique patient population.